Efficacy of FiLaC in different types of anal fistula. A systematic review and meta-analysis.

Lasers Med SciSep 1, 2026 (epub)
Clinical ResearchGeneral SurgeryGastroenterologyOpen access

Xingli Xu, Jiong Wu, Jialin Qin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of Fistula Tract Laser Closure (FiLaC) across different types of anal fistula. Analyzing 16 studies, it found that simple fistulae had a healing rate of 60.8%, while complex fistulae had a lower rate of 54.6%. Transsphincteric fistulae showed the best odds of healing among complex types.

Key findings

  • Healing rate for simple fistulae was 60.8%, compared to 54.6% for complex fistulae.
  • Transsphincteric fistulae had the best odds of healing following FiLaC.
  • Extrasphincteric and suprasphincteric fistulae had a success rate of about 50%.

Why it matters

Understanding the varying success rates of FiLaC for different anal fistula types can guide clinicians in selecting appropriate treatment strategies, potentially improving patient outcomes in this challenging condition.

Source

PubMed · PMID 42678555Free full text on PubMed Central

Published in Lasers Med Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.